Pfizer Wins US Patent Case with Astellas and Gilead Over Generic Lexiscan

Pfizer was granted a win by the US Court of Appeals for the Federal Circuit in its legal battle with Astellas and Gilead. The case centered around the active ingredient in Hospira, which is also the active ingredient in Astellas and Gilead’s myocardial perfusion imaging drug Lexiscan. The court decided that Hospira didn’t pose any direct infringement on Gilead and Astellas’ patents.

According to Katherine Lewin, “Astellas alleged that Hospira’s generic infringed on three patents for a form of regadenoson that can be used to increase blood flow to mimic a cardiac stress test. Astellas’ theory was that a third party working with Hospira produced an intermediate product that infringed on its patents.”

To read more, click here.

(Source: Endpoints News, January 4^th, 2022)